Robin Lewis Jones

**Please do not contact me via DM with clinical or professional queries - contact my PA at sarcoma.medsecchelsea@rmh.nhs.uk**

Fred Hutch has built a robust portfolio of targeted therapies for lung cancer, but the next challenge is bigger: helping patients without oncogene‑driven or immunotherapy‑sensitive disease. 🎧 @PGrivasMDPhD's full conversation with Dr. Christina Baik: bit.ly/4cS2JYA

Honored to Receive The ESMO Merit Award - Amalya Sargsyan @amalsargsyan @myESMO oncodaily.com/voices/amalya-… #OncoDaily #Oncology #Cancer #Health #Medicine #Sarcoma #CancerResearch #MedX #MedTwitter

Dr #SandraDAngelo took us through the journey of how #sarcomas became the first solid tumour to #establish #celltherapy as a #treatmentparadigm, and discussed what is on the horizon with potential to further improve #outcomes.

Followed by @pawel_sobczuk showcasing #strategic and #rational #combinations of #IOagents together with other #systemictreatments 💊💉 or #radiotherapy ☢️

The #statusquo of #immunotherapy was challenged at @myesmo #ESMORareCancer26 during a dedicated session. Kicked off by Prof. #AntoineItaliano outlining 'established' and 'emerging' #biomarkers and #immune profiling, together with on-going projects in this field

Very happy to participate once more to ESMO Sarcoma and Rare Cancers Congress!

In #RareCancers, guidelines are vital to bring together scattered expertise. A recent EURACAN survey highlights a high uptake of recommendations from oncologists, potentially leading to improved patients’ survival. #ESMORareCancers26 #ESMODailyReporter ow.ly/uREp50YsIRE

Busy couple of weeks. Participated in meetings at @GeorgetownLaw (affordability of cancer drugs), @JHUCarey (innovation in healthcare), and @ClintonFdn (breast cancer research funding).

Our team is in Lugano for the #ESMORareCancers26! We are excited to share our updated data from our ozekibart (#INBRX109) program in #EwingSarcoma, which was presented by Dr. Ana Sebio as part of the scientific program.

Claudins - The Next Big Solid Tumor Target? A major 2026 review in Nature Reviews Cancer dissects why CLDN proteins are rapidly emerging as precision oncology targets Here’s what every oncologist should know: 🧬 What are Claudins? Tight junction transmembrane proteins maintaining epithelial polarity. Frequently dysregulated and overexpressed across solid tumors. 🔥 Why they matter in cancer •Promote proliferation •Drive EMT & stemness •Modulate fibrosis •Shape immune microenvironment •Contribute to therapeutic resistance 🎯 Therapeutic breakthrough CLDN18.2 targeting has achieved regulatory approval - validating claudins as druggable surface antigens 🚀 Therapeutic platforms in development •Monoclonal antibodies •ADCs •Bispecific antibodies •CAR-T cells •Intracellular pathway targeting 🧠 Precision angle Surface overexpression + subtype correlation + biomarker-enriched selection = scalable solid tumor strategy. Claudins may follow the HER2 playbook. From barrier proteins to immunotherapy targets. 📖 Full review: Nature Reviews Cancer 2026 #OncoTwitter #MedTwitter #PrecisionOncology #Immunotherapy #TargetedTherapy #GastricCancer #GIOncology #SolidTumors #ADC #CART @NatureRevCancer @ASCO @myESMO @OncoAlert @ESMO_Open

New episode of SurgOnc Today! Dr. Eyal Mor is joined by Drs. Myles Smith, Cornelius Thiels, Anai Kothari, and Heather Lyu to discuss Innovation in Surgical Oncology: Harnessing AI and AR in the Operating Room. Listen now: ow.ly/t5OH50YhCtj

Our @SylvesterCancer research team is launching a unique clinical trial to evaluate how a multimodal exercise program impacts chemotherapy completion, side effects & overall well-being in pediatric & AYA #sarcoma patients. news.med.miami.edu/study-examines…

Proud to see our ADC review recognized as the most downloaded from @NatureRevCancer in 2025! Read it here: nature.com/articles/s4156…

“When you tell a patient, ‘I cannot treat you — go home,’ that is one of the hardest sentences a doctor can say. I wanted to stop saying that.” youtube.com/watch?v=d9pZpJ… Interview with Dr. Jigjidsuren Chinburen, Minister of Health of Mongolia — a pioneering liver cancer surgeon, founder of Mongolia’s liver–pancreas surgical team, architect of the country’s liver transplantation program, and now national health reform leader. @oncodaily @CancerWorldmag @OncoDailyBio @OncoDailyGI @OncoDailyIO

The 2026 edition of FORTRESS took off in the 800 year old „Infirmerie“ at KU Leuven‘s Grand Beguinage

📢Clinico-radiological outcomes after discontinuation of sorafenib in responding patients with #desmoid 💡3-year PFS 75%. All progressive patients responded to sorafenib or active surveillance.@KinjalSinghx #AIIMS, Delhi 🇮🇳 sciencedirect.com/science/articl…

@samdoc_mamc @KinjalSinghx @RashiKapoor17 @SachinSarcoma @DTRFoundation @RobinL_Jones @12crc @DesmoidI @ejcancer Congratulations Sir, Kinjal! 👏 🎉 Amazing! 🤩

@samdoc_mamc @KinjalSinghx @SachinSarcoma @DTRFoundation @sorunshishak @RobinL_Jones @12crc @DesmoidI @ejcancer Congratulations Dr Sameer Rastogi. Best wishes.

We don't want PNAS to publish science any more. We want more advice on grantsmanship like this. Also more advice on how to schmooze editors, get tenure, crush competitors, and maybe what to wear at conferences.

Why does mathematics compel certainty in a way science does not? Is math invented by humans or discovered as part of reality? What does the effectiveness of mathematics say about materialism? Does mathematical beauty point to a deeper order in the universe? Watch and find out.